Ueli Nachbur

Years Active: 2019-2021
Publications (10 Years): 3

Anaxis Pharma

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Anaxis Pharma Sep 01 2017

Australia

Biology Lead

Walter and Eliza Hall Institute of Medical Research Mar 01 2011

Australia

Senior Research Officer :: Inflammation

Publications

Zikou Liu, Laura F Dagley, Kristy Shield-Artin, Samuel N Young, Aleksandra Bankovacki, Xiangyi Wang, Michelle Tang, Jason Howitt, Che A Stafford, Ueli Nachbur, Cheree Fitzgibbon, Sarah E Garnish, Andrew Ian Webb, David Komander, James G Murphy, Joanne M Hildebrand, John Silke
Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis. The EMBO journal 40 (23) (2021)
Valentin J Heim, Laura F Dagley, Che A Stafford, Fynn M Hansen, Elise Clayer, Aleksandra Bankovacki, Andrew I Webb, Isabelle S Lucet, John Silke, Ueli Nachbur
A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity. EMBO reports 21 (11) (2020)
Kornelia Ellwanger, Selina Briese, Christine Arnold, Ioannis Kienes, Valentin Heim, Ueli Nachbur, Thomas A Kufer
XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures. Life science alliance 2 (4) (2019)

Ueli Nachbur.css-eqlu8i{font-size:small;padding-left:4px;}